N/A
N=229
USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19
Covid19
Bottom Line
View on ClinicalTrials.gov: NCT04425850 ↗Enrolled (actual)
229
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcome: Primary: Number of Infected Subjects — 0; 11 Participants — p=< 0.0001
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops) (Combination_product)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Eurnekian Public Hospital
- Primary completion
- Aug 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Infected Subjects |
0; 11 | < 0.0001 sig |
| SECONDARY Adverse Events Other Than Those Resulting From Contagion or Disease Progression |
0; 0 | — |
Summary
Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease.
It is estimated that 86% of all infections were undocumented [95% credible interval (CI): 82-90%] before the 23 January 2020 travel restrictions. The transmission rate of undocumented infections per person was 55% the transmission rate of documented infections (95% CI: 46-62%), yet, because of their greater numbers, undocumented infections were the source of 79% of the documented cases.
Ivermectin + Carrageenan, taking advantage of their virucidal effects, are aimed at reducing the contagion.
Eligibility Criteria
Inclusion criteria
- Not younger than 18 years of either sex
- Health personnel from the Dr. Alberto Eurnekian Interzonal University Hospital
- No COVID-19 related symptoms
- Able to understand and give written informed consent
Exclusion criteria
- Known hypersensitivity or allergy to any component of the product under evaluation
- Age under 18 years
- Use of immunosuppressants (including systemic corticosteroids) in the past 30 days.
- Pregnant or nursing.
- Patients with other acute infectious diseases.
- Patients with autoimmune disease and / or decompensated chronic diseases.
- Unable to fulfill the administrative tasks proposed by the study.
- Infection with SARSCoV-2 confirmed by PCR or rapid test authorized by ANMAT.
Data sourced from ClinicalTrials.gov (NCT04425850). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.